A study of docetaxel and irinotecan in children and young adults with recurrent or refractory Ewing sarcoma family of tumors

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Yoon, Jong H ^a   Kwon, Mi M ^a   Park, Hyeon J ^a   Park, Seog Y ^a   Lim, Kun Y ^a   Joo, Jungnam ^a   Park, Byung Kiu ^a  

^a National Cancer Center   (South Korea)

Author keywords

Docetaxel; Ewing sarcoma family of tumors; Irinotecan; Recurrent; Refractory

Indexed keywords

DOCETAXEL; IRINOTECAN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; TAXOID;

ABDOMINAL PAIN; ABSCESS; ADOLESCENT; ADULT; ARTICLE; CANCER SURGERY; CANCER SURVIVAL; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSGEUSIA; EDEMA; EWING SARCOMA; EYE INFECTION; FEBRILE NEUTROPENIA; FEMALE; HEADACHE; HUMAN; LEUKOPENIA; MALE; MULTIPLE CYCLE TREATMENT; MUSCLE WEAKNESS; NAIL INFECTION; NAUSEA; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; ORAL MUCOSITIS; ORBIT CELLULITIS; PERICARDIAL EFFUSION; PERIPHERAL NEUROPATHY; PLEURA EFFUSION; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; SEPTICEMIA; THORAX PAIN; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREMOR; VOMITING; ANALOGS AND DERIVATIVES; BONE NEOPLASMS; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY; PRESCHOOL CHILD; SARCOMA, EWING; YOUNG ADULT;

ADOLESCENT; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; CAMPTOTHECIN; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; PROSPECTIVE STUDIES; SARCOMA, EWING; TAXOIDS; YOUNG ADULT;

EID: 84910100417     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-622     Document Type: Article

References (25)

1. Linet MS, Ries LA, Smith MA, Tarone RE, Devesa SS. Cancer surveillance series: recent trends in childhood cancer incidence and mortality in the United States. J Natl Cancer Inst 1999, 91:1051-1058. 10.1093/jnci/91.12.1051, 10379968.
2. Balamuth NJ, Womer RB. Ewing's sarcoma. Lancet Oncol 2010, 11:184-192. 10.1016/S1470-2045(09)70286-4, 20152770.
3. Rodríguez-Galindo C, Liu T, Krasin MJ, Wu J, Billups CA, Daw NC, Spunt SL, Rao BN, Santana VM, Navid F. Analysis of prognostic factors in Ewing sarcoma family of tumors: review of St. Jude Children's Research Hospital studies. Cancer 2007, 110:375-384. 10.1002/cncr.22821, 17569105.
4. Granowetter L, Womer R, Devidas M, Krailo M, Wang C, Bernstein M, Marina N, Leavey P, Gebhardt M, Healey J, Shamberger RC, Goorin A, Miser J, Meyer J, Arndt CA, Sailer S, Marcus K, Perlman E, Dickman P, Grier HE. Dose-intensified compared with standard chemotherapy for nonmetastatic Ewing sarcoma family of tumors: a Children's Oncology Group study. J Clin Oncol 2009, 27:2536-2541. 10.1200/JCO.2008.19.1478, 2684856, 19349548.
5. Kolb EA, Kushner BH, Gorlick R, Laverdiere C, Healey JH, LaQuaglia MP, Huvos AG, Qin J, Vu HT, Wexler L, Wolden S, Meyers PA. Long-term event-free survival after intensive chemotherapy for Ewing's family of tumors in children and young adults. J Clin Oncol 2003, 21:3423-3430. 10.1200/JCO.2003.10.033, 12972518.
6. Barker LM, Pendergrass TW, Sanders JE, Hawkins DS. Survival after recurrence of Ewing sarcoma family of tumors. J Clin Oncol 2005, 23:4354-4362. 10.1200/JCO.2005.05.105, 15781881.
7. Hunold A, Weddeling N, Paulussen M, Ranft A, Liebscher C, Jürgens H. Topotecan and cyclophosphamide in patients with refractory or relapsed Ewing tumors. Pediatr Blood Cancer 2006, 47:795-800. 10.1002/pbc.20719, 16411206.
8. van Winkle P, Angiolillo A, Krailo M, Cheung YK, Anderson B, Davenport V, Reaman G, Cairo MS. Ifosfamide, carboplatin, and etoposide (ICE) reinduction chemotherapy in a large cohort of children and adolescents with recurrent/refractory sarcoma: The Children's Cancer Group (CCG) experience. Pediatr Blood Cancer 2005, 44:338-347. 10.1002/pbc.20227, 15503297.
9. Wagner LM, McAllister N, Goldsby RE, Rausen AR, McNall-Knapp RY, McCarville MB, Albritton K. Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma. Pediatr Blood Cancer 2007, 48:132-139. 10.1002/pbc.20697, 16317751.
10. Mora J, Cruz CO, Parareda A, de Torres C. Treatment of relapsed/refractory pediatric sarcomas with gemcitabine and docetaxel. J Pediatr Hematol Oncol 2009, 31:723-729. 10.1097/MPH.0b013e3181b2598c, 19727011.
11. Zwerdling T, Krailo M, Monteleone P, Byrd R, Sato J, Dunaway R, Seibel N, Chen Z, Strain J, Reaman G. Phase II investigation of docetaxel in pediatric patients with recurrent solid tumors: a report from the Children's Oncology Group. Cancer 2006, 106:1821-1828. 10.1002/cncr.21779, 16532433.
12. Bisogno G, Riccardi R, Ruggiero A, Arcamone G, Prete A, Surico G, Provenzi M, Bertolini P, Paolucci P, Carli M. Phase II study of a protracted irinotecan schedule in children with refractory or recurrent soft tissue sarcoma. Cancer 2006, 106:703-707. 10.1002/cncr.21629, 16369989.
13. Bissery MC, Vrignaud P, Lavelle F. In vivo evaluation of docetaxel-iriniotecan combination. Proc Am Assoc Cancer Res 1996, 37:A2578.
14. Bleickardt E, Argiris A, Rich R, Blum K, McKeon A, Tara H, Zelterman D, Burtness B, Davies MJ, Murren JR. Phase 1 dose escalation trial of weekly docetaxel plus iriniotecan in patients with advanced cancer. Cancer Biol Ther 2002, 1:646-651. 10.4161/cbt.314, 12642688.
15. Bomgaars LR, Bernstein M, Krailo M, Kadota R, Das S, Chen Z, Adamson PC, Blaney SM. Phase II trial of irinotecan in children with refractory solid tumors: a Children's Oncology Group study. J Clin Oncol 2007, 25:4622-4627. 10.1200/JCO.2007.11.6103, 17925558.
16. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 2009, 45:228-247. 10.1016/j.ejca.2008.10.026, 19097774.
17. Casey DA, Wexler LH, Merchant MS, Chou AJ, Merola PR, Price AP, Meyers PA. Irinotecan and temozolomide for Ewing sarcoma: The Memorial Sloan-Kettering experience. Pediatr Blood Cancer 2009, 53:1029-1034. 10.1002/pbc.22206, 19637327.
18. Raciborska A, Bilska K, Drabko K, Chaber R, Pogorzala M, Wyrobek E, Polczyńska K, Rogowska E, Rodriguez-Galindo C, Wozniak W. Vincristine, irinotecan, and temozolomide in patients with relapsed and refractory Ewing sarcoma. Pediatr Blood Cancer 2013, 60:1621-1625. 10.1002/pbc.24621, 23776128.
19. Hawkes E, Okines AF, Papamichael D, Rao S, Ashley S, Charalambous H, Koukouma A, Chau I, Cunningham D. Docetaxel and irinotecan as second-line therapy for advanced oesophagogastric cancer. Eur J Cancer 2011, 47:1146-1151. 10.1016/j.ejca.2010.12.021, 21269822.
20. Sym SJ, Chang HM, Kang HJ, Lee SS, Ryu MH, Lee JL, Kim TW, Yook JH, Oh ST, Kim BS, Kang YK. A phase II study of irinotecan and docetaxel combination chemotherapy for patients with previously treated metastatic or recurrent advanced gastric cancer. Cancer Chemother Pharmacol 2008, 63:1-8. 10.1007/s00280-008-0701-2, 18288477.
21. Yamamoto N, Fukuoka M, Negoro SI, Nakagawa K, Saito H, Matsui K, Kawahara M, Senba H, Takada Y, Kudoh S, Nakano T, Katakami N, Sugiura T, Hoso T, Ariyoshi Y. Randomized phase II study of docetaxel/cisplatin versus docetaxel/irinotecan in advanced non-small-cell lung cancer: a West Japan Thoracic Oncology Group study (WJTOG9803). Br J Cancer 2004, 90:87-92. 10.1038/sj.bjc.6601462, 2395326, 14710212.
22. Seibel NL, Blaney SM, O'Brien M, Krailo M, Hutchinson R, Mosher RB, Balis FM, Reaman GH. Phase I trial of docetaxel with filgrastim support in pediatric patients with refractory solid tumors: a collaborative Pediatric Oncology Branch, National Cancer Institute and Children's Cancer Group trial. Clin Cancer Res 1999, 5:733-737.
23. Bria E, Cuppone F, Ciccarese M, Nisticò C, Facciolo F, Milella M, Izzo F, Terzoli E, Cognetti F, Giannarelli D. Weekly docetaxel as second line chemotherapy for advanced non-small-cell lung cancer: meta-analysis of randomized trials. Cancer Treat Rev 2006, 32:583-587. 10.1016/j.ctrv.2006.07.003, 16919884.
24. Tabernero J, Climent MA, Lluch A, Albanell J, Vermorken JB, Barnadas A, Anton A, Laurent C, Mayordomo JI, Estaun N, Losa I, Guillem V, Garcia-Conde J, Tisaire JL, Baselga J. A multicenter, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer. Ann Oncol 2004, 15:1358-1365. 10.1093/annonc/mdh349, 15319242.
25. Bacci G, Ferrari S, Longhi A, Donati D, De Paolis M, Forni C, Versari M, Setola E, Briccoli A, Barbieri E. Therapy and survival after recurrence of Ewing's tumors: the Rizzoli experience in 195 patients treated with adjuvant and neoadjuvant chemotherapy from 1979 to 1997. Ann Oncol 2003, 14:1654-1659. 10.1093/annonc/mdg457, 14581274.